AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUL 17 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - A therapeutic vaccine containing plasmid DNA that codes for the human papillomavirus (HPV) provoked an immune response in patients with HPV-related anal dysplasia, researchers in the U.S. found.
"High-grade dysplasia induced by high-risk types of human papillomavirus (HPV) precedes invasive cancer in anal squamous epithelium just as it does in the cervix," said B. Klencke and collaborators at University of California at San Francisco.
The investigators performed a phase I, dose-escalation trial to test the safety of the vaccine and its ability to elicit an immune response against HPV. The vaccine, ZYC101, consisted of biodegradable microparticles enclosing plasmid DNA coding for the E7 protein of HPV-16, one of the two proteins expressed by dysplastic cells.
Screening tests done on 56 patients identified 12 with HPV-16 anal infections. Each of the patients eligible for the trial received a total of four ZYC101 intramuscular injections, 50 [micro sign]g to 400 [micro sign]g, 1 every 3 weeks (Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: A phase I study of ZYC101, Clinical Cancer Research, 2002;8(5):1028-1037).
...